What Happens to Infants Whose Mothers Took Anti-TNF Agents During Pregnancy?

Anti-tumor necrosis factor (TNF) agents can be detected in infants born to mothers with inflammatory bowel diseases (IBD) who took the drugs during pregnancy, researchers report in the July issue of Gastroenterology. Infliximab is cleared more slowly than adalimumab from infants. However, measureable levels in infants do not seem to be

Read more

Should Patients with Crohn’s Disease Continue Receiving Immunomodulators When Starting Anti-TNF Therapy?

Continued use of immunomodulator therapy in patients with Crohn’s disease receiving anti-tumor necrosis factor (TNF) therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission, researchers show. The meta-analysis of randomized controlled trials is published in the December issue of Clinical Gastroenterology and Hepatology. There is debate

Read more

Curbing Crohn’s for the Long Term?

Most people with Crohn’s disease receive surgery, yet the disease comes back a short time later. A study in the July issue of Clinical Gastroenterology and Hepatology reports that giving patients low doses of infliximab immediately after surgery prevents disease recurrence over long time periods. Dario Sorrentino et al. began

Read more